Promising drug targets rare protein disease in phase 2 trial
NCT ID NCT04617925
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 41 times
Summary
This study tested a drug called belantamab mafodotin in 35 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. All participants had already received at least one prior treatment. The goal was to see how many patients achieved a significant reduction in disease markers, while also monitoring side effects. The trial is complete, and results will help determine if this drug offers a new option for controlling this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier Universitaire de Limoges -
Limoges, 87042, France
-
Fondazione I.R.C.C.S Policlinico "San Matteo"
Pavia, 27100, Italy
-
General Hospital of Athens "Alexandra"
Athens, 115 28, Greece
-
Royal Free Hospital - London,
London, United Kingdom
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
University Hospital Heidelberg
Heidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.